ArticleBMC ophthalmology2022
Diabetic retinopathy with extensively large area of capillary non-perfusion: characteristics and treatment outcomes.
Article in BMC ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 8 citations in OpenAlex.
- MAGIC: Study Design and Rationale for the Phase 2 Clinical Trial of Faricimab for Non-Proliferative Diabetic Retinopathy.Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde · 2026Trial
- Short-term natural history of non-perfusion areas in treatment-naive diabetic retinopathy patients using swept-source OCT angiography.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Macular, Peripapillary, and Midperipheral Nonperfusion in Diabetic Subjects: A Wide-Field OCTA Quantification.Translational vision science & technology · 2026Article
- Assessment of glycemic control among patients undergoing surgical treatment for advanced diabetic retinopathy in Saudi Arabia.International journal of retina and vitreous · 2026Article
- Erythrocyte deformability correlates with microvascular ischemia and disease severity in diabetic retinopathy.Journal of diabetes investigation · 2026Article
- Predictors of Peripheral Retinal Non-Perfusion in Clinically Significant Diabetic Macular Edema.Journal of clinical medicine · 2024Article
- Retinal non-perfusion: recognizing and defining what is important.Eye (London, England) · 2024Article
- The Treatment of Diabetic Retinal Edema with Intravitreal Steroids: How and When.Journal of clinical medicine · 2024Review
- Retinal Ischaemia in Diabetic Retinopathy: Understanding and Overcoming a Therapeutic Challenge.Journal of clinical medicine · 2023Review
- Peripheral and central capillary non-perfusion in diabetic retinopathy: An updated overview.Frontiers in medicine · 2023Review
- The role of ceramides in the pathophysiology of diabetic retinopathy: Mechanisms and Implications for therapeutic strategies.Diabetes & vascular disease researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCapillary non-perfusion is an important characteristic for diabetic retinopathy (DR) indicating microvascular damage and ischemia. Data on the description and treatment outcomes of DR with large area of non-perfusion are lacking to date. We aim to describe the characteristics and treatment outcomes in a series of patients with DR who presented extensively large area of capillary non-perfusion (LACNP).
methodsFundus fluorescein angiograms from medical charts in patients diagnosed with DR between Jan 2017 and Dec 2019 were retrospectively reviewed. Clinical data in eyes with LACNP including imaging and laboratory findings at the first presentation were analyzed. The LACNP was defined as over 70% area of capillary non-perfusion throughout the whole image retina. The mean follow-up duration was 12.4 ± 16.7 months. Follow-up data including extensive pan-retinal photocoagulation and surgical intervention and treatment outcomes were evaluated.
resultsA total of 43 eyes in 24 patients with LACNP were included, accounting for 3.3% of DR populations in the same period. The overall percentage of non-perfusion area was 79.1 ± 8.1%. All patients received proper control of diabetes and hypertension, and extensive pan-retinal laser photocoagulation. During the follow-up periods, 20 eyes (46.5%) developed severe neovascular complications, of which 15 eyes (34.9%) underwent vitrectomy and/or anti-glaucoma surgeries. Conservative therapies including glycemic control and supplemental laser photocoagulation were conducted in 23 eyes (53.5%) without neovascular complications. In the final follow-up, best corrected visual acuity improved or maintained stable in 19 eyes (44.2%) while deteriorated in 24 eyes (55.8%).
conclusionsThe presence of LACNP is the hallmark of advanced DR and often indicates a poor visual outcome, although aggressive treatments may slow DR progression and maintain central vision for some time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.